1311 completed, 238 unknown, 210 recruiting, 84 active not recruiting. 1337 Not applicable, 193 Phase 2, 123 Phase 3, 86 Phase 1, 83 Phase 4.
Follow Weight Loss: new trials by email Literature Review of Weight Loss trials Research Report on Weight Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Simplifying Diet Tracking in a Digital Weight Loss Intervention Simplified Dietary Self-Monitoring, Detailed Dietary Self-Monitoring, Core Behavioral Weight Loss Intervention - Overweight, Obesity | Not applicable | Not yet recruiting | Stanford University | 328 | 2027-05-01 | 2026-05-28 |
| Optimization of Dietary Adherence in a Mobile Weight Loss Intervention Core, Switch to Simplified Diet Monitoring, Goal Autonomy/Planning - Overweight and/or Obesity | Not applicable | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 580 | 2027-03-01 | 2026-05-15 |
| OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 400 | 2027-02-01 | 2026-10-22 |
| Addressing Food Access and Physical Activity to Improve Diabetes Prevention Outcomes Among Underserved African Americans Culturally-tailored, enhanced adaption of Diabetes Prevention Program - Diabetes, Physical Activity | Not applicable | Not yet recruiting | University of Missouri, Kansas City | 408 | 2027-01-04 | 2026-06-09 |
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program - Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 48 | 2027-01-01 | 2026-10-01 |
| Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) Endothelial cell collection - Obesity and Obesity-related Medical Conditions, Diabetes | Recruiting | Bettina Mittendorfer | 100 | 2027-01-01 | 2026-05-07 | |
| Diabetes Prevention Through Genetics, Familial History and Behavior Change LEGACY DPP, DPP - Prediabetes, Weight Loss | Phase 2 / Phase 3 | Not yet recruiting | Morehouse School of Medicine | 400 | 2027-01-01 | 2026-10-20 |
| Weight Changes After Incretin-mimetics discontinuation of weight loss medication - Obesity and Obesity-related Medical Conditions | Not applicable | Not yet recruiting | Medical College of Wisconsin | 52 | 2026-12-01 | 2026-02-24 |
| Weight Loss Composition and Metabolic Adaptation During Hypocaloric Dieting Hypocaloric Diet - Obesity | Not applicable | Not yet recruiting | Tel Aviv University | 150 | 2026-12-01 | 2026-10-08 |
| A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia SXRN Injection, Placebo - Cachexia-Anorexia Syndrome, Cachexia; Cancer | Phase 2 | Not yet recruiting | Jiangsu Guiqiong Pharmaceutical Co., Ltd. | 96 | 2026-12-01 | 2026-10-22 |
| Building Opportunities for Nurturing Care to Enhance Child Development in Eastern and Southern Africa Friendship Bench, Infant and Young Child Feeding (IYCF) Curriculum, Play-Based Curriculum - Neurodevelopment, Child Growth | Not applicable | Not yet recruiting | University of Washington | 1260 | 2026-11-01 | 2026-03-03 |
| Feasibility Testing of Plant-Based Supplemented Food Products Made With Manitoba Crop Ingredients for Weight Loss Supplemented Food - Weight Loss | Not applicable | Not yet recruiting | University of Manitoba | 40 | 2026-11-01 | 2026-09-21 |
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) VK2735, Placebo comparator - Weight Loss | Phase 3 | Not yet recruiting | Viking Therapeutics, Inc. | 560 | 2026-11-01 | 2026-10-16 |
| Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation Weight Loss Maintenance Program (Foundational), Mom's Meals, YMCA Membership - Weight Loss, GLP - 1 | Not applicable | Not yet recruiting | University of Alabama at Birmingham | 64 | 2026-11-01 | 2026-06-26 |
| Personalised Nutritional Care in Older Patients With Pancreatic Ductal Adenocarcinoma Experimental: Personalised nutritional care delivered by a trained dietitian - Pancreatic Cancer | Not applicable | Not yet recruiting | Inna Chen, MD | 250 | 2026-11-01 | 2026-09-16 |
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) VK2735 Oral, Placebo Comparator - Weight Loss | Phase 3 | Not yet recruiting | Viking Therapeutics, Inc. | 560 | 2026-11-01 | 2026-10-16 |
| A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes LY4086940, Placebo - Obesity, Overweight | Phase 2 | Not yet recruiting | Eli Lilly and Company | 460 | 2026-11-01 | 2026-10-22 |
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity Olatorepatide, Placebo - Hidradenitis Suppurativa | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 300 | 2026-10-30 | 2026-09-21 |
| A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss ponsegromab, placebo - Non-small Cell Lung Cancer (NSCLC), Cachexia | Phase 1 | Not yet recruiting | Pfizer | 80 | 2026-10-23 | 2026-09-25 |
| Polydextrose Functional Gummies for Weight Management in Adults With Overweight or Obesity Polydextrose Gummies, Placebo Gummies - Obesity & Overweight | Not applicable | Not yet recruiting | Nutris We Care About You S.L. | 96 | 2026-10-19 | 2026-08-14 |
Showing 20 of 2069. Sign in to see all of them.
Obesity (1102) · Overweight (407) · Cachexia (302) · Motor Activity (229) · Neoplasms (99) · Diabetes Mellitus, Type 2 (90) · Body Weight (84) · Diabetes Mellitus (84) · Obesity, Morbid (82) · Metabolic Syndrome (79) · Insulin Resistance (71) · Malnutrition (68) · Anorexia (58) · Feeding Behavior (48)
Pathological Conditions, Signs and Symptoms (2069) · Signs and Symptoms (2067) · Body Weight Changes (2025) · Body Weight (1985) · Nutritional and Metabolic Diseases (1410) · Nutrition Disorders (1290) · Overnutrition (1199) · Overweight (797) · Behavior (385) · Metabolic Diseases (344) · Glucose Metabolism Disorders (297) · Thinness (289) · Endocrine System Diseases (258) · Neoplasms by Site (161)
Exercise (84) · Diet (52) · Caloric Restriction (47) · semaglutide (25) · Gastric Bypass (22) · Bariatric Surgery (21) · Nutrition Assessment (21) · Standard of Care (20) · Liraglutide (17) · Behavior Therapy (16) · Diet Therapy (16) · Megestrol Acetate (16) · Tirzepatide (14) · Control Groups (12) · Diet, Carbohydrate-Restricted (12)
Wake Forest University Health Sciences (32) · The Miriam Hospital (29) · University of Pittsburgh (22) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (21) · University of Alabama at Birmingham (21) · University of California, San Diego (21) · VA Office of Research and Development (21) · University of North Carolina, Chapel Hill (20) · Duke University (19) · University of Colorado, Denver (19) · University of Pennsylvania (19) · University of Kansas Medical Center (18) · Washington University School of Medicine (18) · Mayo Clinic (17) · Pennington Biomedical Research Center (17)
United States (1051) · Canada (78) · China (70) · United Kingdom (68) · Germany (65) · Denmark (52) · Spain (50) · Italy (46) · France (44) · Turkey (Türkiye) (35) · Norway (31) · Sweden (28) · Netherlands (27) · Taiwan (27) · Brazil (25)
Samuel Klein, MD (8) · David Crowley, MD (5) · Holly Wyatt, MD (5) · James Hill, PhD (5) · Jessica G LaRose, PhD (5) · John M Jakicic, Ph.D. (5) · Aminah Jatoi, MD (4) · Cheryl L Rock, PhD, RD (4) · David S Ludwig, MD, PhD (4) · Hamid R Farshchi, MD, PhD (4) · James O Hill, PhD (4)
PMID 33512717, PMID 38375882, PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28472437, PMID 35538903, PMID 37652841, PMID 40705619, PMID 18753666, PMID 20145731, PMID 20222968, PMID 22085317, PMID 22127229, PMID 22513296, PMID 23229890, PMID 23364004, PMID 24081232, PMID 24500151, PMID 24670075, PMID 25475207, PMID 25972230, PMID 26395743, PMID 26641646, PMID 26906526, PMID 27116910, PMID 27676466, PMID 28494136, PMID 30475957, PMID 30651576, PMID 31004409, PMID 31155473, PMID 31409509, PMID 32002540, PMID 32651241, PMID 33240920, PMID 33677781, PMID 33789551, PMID 34544560, PMID 34714976, PMID 35562076, PMID 36375643, PMID 36796647, PMID 36999619, PMID 37182692, PMID 38055284, PMID 39992021, PMID 42665333, PMID 10534586
R01AG012161 (4), 2023 (3), P20GM144269 (3), 2018 (2), 8UL1GM118979-02 (2), K01HL141535 (2), K23AG051681 (2), K24DK065018 (2), P30CA069533 (2), P30DK116074 (2), P60MD006917 (2), R01AG025501 (2), R01AT001103 (2), R01CA127971 (2), R01DK099334 (2)